Should I buy or sell Orthofix Medical stock right now?

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares. View OFIX analyst ratings or view top-rated stocks .

What is Orthofix Medical's stock price target for 2024?

3 Wall Street research analysts have issued 12-month price targets for Orthofix Medical's shares. Their OFIX share price targets range from $12.00 to $16.00. On average, they expect the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price. View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts .

How have OFIX shares performed in 2023?

Orthofix Medical's stock was trading at $20.53 at the beginning of the year. Since then, OFIX stock has decreased by 49.1% and is now trading at $10.45. View the best growth stocks for 2023 here .

When is Orthofix Medical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024. View our OFIX earnings forecast .

How were Orthofix Medical's earnings last quarter?

Orthofix Medical Inc. (NASDAQ:OFIX) issued its earnings results on Wednesday, November, 8th. The medical device company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.02. The medical device company had revenue of $184.01 million for the quarter, compared to the consensus estimate of $185.50 million. Orthofix Medical had a negative net margin of 20.39% and a negative trailing twelve-month return on equity of 7.26%.

What ETF holds Orthofix Medical's stock ?

Syntax Stratified SmallCap ETF holds 3,764 shares of OFIX stock, representing 0.39% of its portfolio.

What is Brad Mason's approval rating as Orthofix Medical's CEO?

32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com . Brad Mason has an approval rating of 73% among the company's employees.

What other stocks do shareholders of Orthofix Medical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV) , Enterprise Products Partners (EPD) , Edwards Lifesciences (EW) , Gilead Sciences (GILD) , Biogen (BIIB) , Pfizer (PFE) , Exxon Mobil (XOM) , Advanced Micro Devices (AMD) , bluebird bio (BLUE) and Esperion Therapeutics (ESPR) .

Who are Orthofix Medical's major shareholders?

Orthofix Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Rubric Capital Management LP (9.35%), Armistice Capital LLC (8.07%), AWM Investment Company Inc. (1.63%), Assenagon Asset Management S.A. (1.55%), Emerald Advisers LLC (1.53%) and Emerald Mutual Fund Advisers Trust (1.25%). Insiders that own company stock include Catherine M Burzik , James F Hinrichs, Jon Carl Serbousek , Kevin J Kenny, Kimberley A Elting , Michael E Paolucci , Rice Doug and Shweta Maniar. View institutional ownership trends .

How do I buy shares of Orthofix Medical?

Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Orthofix Medical Stock Price, News & Analysis (NASDAQ:OFIX)

$10.79

+0.34 (+3.25%)

(As of 11:27 AM ET)

Compare

Today's Range: $10.46
▼
$10.88
50-Day Range: $9.69
▼
$13.07
52-Week Range: $9.57
▼
$23.19

Volume: 113,881 shs
Average Volume: 433,182 shs
Market Capitalization: $396.61 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $14.00

Orthofix Medical MarketRank™ Stock Analysis

Analyst Rating: Hold
2.00 Rating Score
Upside/Downside: 34.0% Upside
$14.00 Price Target
Short Interest: Bearish
9.09% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.05
Based on 4 Articles This Week
Insider Trading: Acquiring Shares
$101,025 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($3.16) to ($1.40) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.95 out of 5 stars

Medical Sector

607th out of 948 stocks

Medical Devices Industry

12th out of 17 stocks

3.0

Analyst's Opinion

Consensus Rating
Orthofix Medical has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $14.00, Orthofix Medical has a forecasted upside of 34.0% from its current price of $10.45.
Amount of Analyst Coverage
Orthofix Medical has only been the subject of 3 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.09% of the outstanding shares of Orthofix Medical have been sold short.
Short Interest Ratio / Days to Cover
Orthofix Medical has a short interest ratio ("days to cover") of 4.6.
Change versus previous month
Short interest in Orthofix Medical has recently increased by 12.08%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Orthofix Medical does not currently pay a dividend.
Dividend Growth
Orthofix Medical does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for OFIX.

1.7

News and Social Media Coverage

News Sentiment
Orthofix Medical has a news sentiment score of 0.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.39 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 4 news articles for Orthofix Medical this week, compared to 4 articles on an average week.
Search Interest
Only 1 people have searched for OFIX on MarketBeat in the last 30 days. This is a decrease of -75% compared to the previous 30 days.
MarketBeat Follows
2 people have added Orthofix Medical to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Orthofix Medical insiders have bought more of their company's stock than they have sold. Specifically, they have bought $101,025.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
Only 4.70% of the stock of Orthofix Medical is held by insiders.
Percentage Held by Institutions
89.76% of the stock of Orthofix Medical is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Orthofix Medical are expected to grow in the coming year, from ($3.16) to ($1.40) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Orthofix Medical is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Orthofix Medical is -2.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Orthofix Medical has a P/B Ratio of 0.63. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Orthofix Medical Stock (NASDAQ:OFIX)

Orthofix Medical Inc. operates spine and orthopedics company in the United States, Italy, Germany, France, the United Kingdom, Brazil, and internationally. It operates through Global Spine and Global Orthopedics segments. The Global Spine segment comprises the bone growth therapies products, which manufactures and distributes bone growth stimulator devices for enhance of bone fusion including adjunctive and noninvasive treatment of cervical and lumbar spine as well as a therapeutic treatment for non-spine; the spinal implants products designs, develops, and markets a portfolio of motion preservation and fixation implant products, which are used in surgical procedures of the spine; and the biological products, such as regenerative products and tissue forms which allow physicians to treat a variety of spinal and orthopedic conditions. Global Orthopedics segment offers products and solutions that allow physicians to treat a variety of orthopedic conditions unrelated to the spine, which design, develop, and market the orthopedic products used in fracture repair, deformity correction, and bone reconstruction procedures. It sells its products through distributors, sales representatives, hospitals, and healthcare providers. The company was formerly known as Orthofix International N.V. and changed its name to Orthofix Medical Inc. in 2018. Orthofix Medical Inc. was founded in 1987 and is headquartered in Lewisville, Texas.

OFIX Stock Price History

30 days | 90 days | 365 days | Advanced Chart

OFIX Stock News Headlines

December 4, 2023 | seekingalpha.com

Orthofix Medical: Under New Management

December 2, 2023 | markets.businessinsider.com

Orthofix Medical: Hold Rating Affirmed Amid Leadership Changes and Integration Challenges

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

Thanks to a new discovery linked to shares of Tesla, regular folks can now target gains of 100% or more in six days or less. New research shows it’s happened 23 different times this year. The next trade is scheduled for this Thursday.

December 1, 2023 | benzinga.com

Spinal Implants Market size to grow by USD 3.57 billion from 2023-2028, North America to account for 43% of market growth - Technavio

November 30, 2023 | americanbankingnews.com

Orthofix Medical (NASDAQ:OFIX) Lowered to "Sell" at StockNews.com

November 23, 2023 | finance.yahoo.com

Does Orthofix (OFIX) Have the Potential to Rally 78.73% as Wall Street Analysts Expect?

November 22, 2023 | finance.yahoo.com

United States Wound Biologics Market Insights 2023-2028: with Avita Medical, Organogenesis, Smith+Nephew, Vericel, and Orthofix Dominating

November 21, 2023 | benzinga.com

SHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate Orthofix Medical Inc. (OFIX) for Potential Violations of Securities Laws

December 6, 2023 | Wealthpress (Ad)

Trading Experts Call It “The Perfect Tesla Trade”

November 9, 2023 | finance.yahoo.com

Orthofix Medical Inc. (NASDAQ:OFIX) Q3 2023 Earnings Call Transcript

November 7, 2023 | markets.businessinsider.com

What Wall Street expects from Orthofix Medical's earnings

November 6, 2023 | markets.businessinsider.com

Orthofix Medical Announces Launch Of WaveForm L Lateral Lumbar Interbody System - Quick Facts

November 6, 2023 | finance.yahoo.com

Orthofix Announces Full Commercial Launch of the WaveForm L Interbody System for Lateral Lumbar Fusion Procedures

October 22, 2023 | barrons.com

Orthofix Medical Inc. (OFIX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings

October 21, 2023 | msn.com

Roth MKM Initiates Coverage of Orthofix Medical (OFIX) with Neutral Recommendation

October 18, 2023 | finance.yahoo.com

Orthofix Schedules Third Quarter Earnings Release and Conference Call for November 8, 2023

October 13, 2023 | msn.com

Orthofix’s OsteoCove graft receives US FDA 510k clearance

October 13, 2023 | finance.yahoo.com

Orthofix (OFIX) Soars 6.4%: Is Further Upside Left in the Stock?

October 13, 2023 | theglobeandmail.com

Wolf Haldenstein Adler Freeman & Herz LLP is investigating potential securities fraud claims against Orthofix Medical Inc.

October 12, 2023 | finance.yahoo.com

Orthofix Announces 510k Clearance and Full Commercial Launch of OsteoCove, an Advanced Bioactive Synthetic Graft for use in Spine and Orthopedic Procedures

October 9, 2023 | benzinga.com

Orthofix Medical Investors: Company Investigated by the Portnoy Law Firm

October 9, 2023 | benzinga.com

Hagens Berman Encourages Orthofix Medical (OFIX) Shareholders to Contact the Firm

October 4, 2023 | stockhouse.com

Orthofix Shareholder Alert

October 1, 2023 | theglobeandmail.com

ROSEN, A GLOBALLY RESPECTED LAW FIRM, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation - OFIX

September 27, 2023 | benzinga.com

ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation - OFIX

September 26, 2023 | tmcnet.com

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Orthofix Medical Inc. Investors to Inquire About Securities Class Action Investigation - OFIX

September 26, 2023 | finance.yahoo.com

Implantable Medical Devices Market to grow by USD 51.1 billion from 2022-2027 | North America to account for 45% of market growth - Technavio

See More Headlines

Receive OFIX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Orthofix Medical and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/06/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/04/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Medical Devices
Sub-Industry: Health Care Equipment
Sector: Medical
Current Symbol: NASDAQ:OFIX
CUSIP: N6748L10
CIK: 884624
Web: www.orthofix.com
Phone: (214) 937-2000
Fax: 599 9 461 6978
Employees: 1,092
Year Founded: 1980

Price Target and Rating

Average Stock Price Target: $14.00
High Stock Price Target: $16.00
Low Stock Price Target: $12.00
Potential Upside/Downside: +34.0%
Consensus Rating: Hold
Rating Score (0-4): 2.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.90)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-19,750,000.00
Net Margins: -20.39%
Pretax Margin: -19.99%
Return on Equity: -7.26%
Return on Assets: -5.15%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 2.58
Quick Ratio: 1.13

Sales & Book Value

Annual Sales: $668.46 million
Price / Sales: 0.57
Cash Flow: $1.77 per share
Price / Cash Flow: 5.89
Book Value: $16.71 per share
Price / Book: 0.63

Miscellaneous

Outstanding Shares: 36,757,000
Free Float: 35,029,000
Market Cap: $384.11 million
Optionable: Optionable
Beta: 1.02

Social Links

Beginners Guide To Retirement Stocks

Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report

Key Executives

Ms. Catherine M. Burzik M.A. (Age 73)
Interim CEO & Chair of the Board
Comp: $137.5k
Ms. Kimberley A. Elting (Age 58)
President of Global Orthopedics
Comp: $766.67k
Mr. Kevin J. Kenny (Age 58)
President of Global Spine Business
Comp: $607.64k
Mr. Geoffrey C. Gillespie
VP, Corporate Controller & Interim CFO
Mr. Roberto Donadello
Senior Vice President of Global Operations
Dr. Frank Vizesi Ph.D.
Chief Scientific Officer
Mr. Dan E. Yarbrough
Vice President of Investor Relations
Ms. Jill Mason
Interim Chief Ethics & Compliance Officer and VP of Corporate Counsel
Ms. Suzanne Armstrong
Chief Human Resources Officer
Mr. Ehab M. Esmail (Age 51)
Senior Vice President of Global Quality, Regulatory & Clinical Affairs

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

OFIX Stock Analysis - Frequently Asked Questions

Should I buy or sell Orthofix Medical stock right now?: 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Orthofix Medical in the last twelve months. There are currently 3 hold ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" OFIX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in OFIX, but not buy additional shares or sell existing shares.
View OFIX analyst ratings or view top-rated stocks.
What is Orthofix Medical's stock price target for 2024?: 3 Wall Street research analysts have issued 12-month price targets for Orthofix Medical's shares. Their OFIX share price targets range from $12.00 to $16.00. On average, they expect the company's share price to reach $14.00 in the next twelve months. This suggests a possible upside of 34.0% from the stock's current price.
View analysts price targets for OFIX or view top-rated stocks among Wall Street analysts.
How have OFIX shares performed in 2023?: Orthofix Medical's stock was trading at $20.53 at the beginning of the year. Since then, OFIX stock has decreased by 49.1% and is now trading at $10.45.
View the best growth stocks for 2023 here.
When is Orthofix Medical's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Monday, March 4th 2024.
View our OFIX earnings forecast.
How were Orthofix Medical's earnings last quarter?: Orthofix Medical Inc. (NASDAQ:OFIX) issued its earnings results on Wednesday, November, 8th. The medical device company reported ($0.77) EPS for the quarter, missing the consensus estimate of ($0.75) by $0.02. The medical device company had revenue of $184.01 million for the quarter, compared to the consensus estimate of $185.50 million. Orthofix Medical had a negative net margin of 20.39% and a negative trailing twelve-month return on equity of 7.26%.
What ETF holds Orthofix Medical's stock ?: Syntax Stratified SmallCap ETF holds 3,764 shares of OFIX stock, representing 0.39% of its portfolio.

What is Brad Mason's approval rating as Orthofix Medical's CEO?: 32 employees have rated Orthofix Medical Chief Executive Officer Brad Mason on Glassdoor.com. Brad Mason has an approval rating of 73% among the company's employees.
What other stocks do shareholders of Orthofix Medical own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Orthofix Medical investors own include AbbVie (ABBV), Enterprise Products Partners (EPD), Edwards Lifesciences (EW), Gilead Sciences (GILD), Biogen (BIIB), Pfizer (PFE), Exxon Mobil (XOM), Advanced Micro Devices (AMD), bluebird bio (BLUE) and Esperion Therapeutics (ESPR).
Who are Orthofix Medical's major shareholders?: Orthofix Medical's stock is owned by many different retail and institutional investors. Top institutional investors include Rubric Capital Management LP (9.35%), Armistice Capital LLC (8.07%), AWM Investment Company Inc. (1.63%), Assenagon Asset Management S.A. (1.55%), Emerald Advisers LLC (1.53%) and Emerald Mutual Fund Advisers Trust (1.25%). Insiders that own company stock include Catherine M Burzik, James F Hinrichs, Jon Carl Serbousek, Kevin J Kenny, Kimberley A Elting, Michael E Paolucci, Rice Doug and Shweta Maniar.
View institutional ownership trends.
How do I buy shares of Orthofix Medical?: Shares of OFIX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:OFIX) was last updated on 12/6/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial